Response of 1,5‐anhydroglucitol level to intensive glucose‐ and blood‐pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial
- Selvin, E
- Wang, D
- McEvoy, JW
- Juraschek, SP
- Lazo, M
- Hamet, P
- Cooper, ME
- Marre, M
- Williams, B
- Harrap, S
- Chalmers, J
- Woodward, M
DOIAbstract
BACKGROUND:Low 1,5-anhydroglucitol (1,5-AG) is a marker of glycosuric hyperglycemia. We evaluated 1,5-AG with clinical outcomes and assessed the effects of glucose- and blood pressure-lowering interventions on change in 1,5-AG in type 2 diabetes. METHODS:We measured 1,5-AG in 6,826 stored samples at baseline and a random subsample of 684 participants at the 1-year follow-up visit in the ADVANCE trial. We examined baseline 1,5-AG (<6, 6-10, ≥10 ug/mL) with microvascular and macrovascular events and mortality using Cox regression models during 5 years of follow-up. Using an intention-to-treat approach, we examined 1-year change in 1,5-AG (mean and percent) in response to the glucose- and blood pressure-lowering interventions in the subsample....
Add to ORKG